Ask a Bitcoin Maxi...About Psychedelic Medicine?
An imagined conversation
The Frontier Psychiatrists has enjoyed doing a series of interviews recently. However, editing those can be a real drag—it’s real people, and they might be offended if I put words in their mouths. Today’s interview is with a fictitious character pulled out of thin air.
As a brief promotional message, remember to buy my books (affiliate links):
Adolescent Suicide and Self-Injury
The Hellthread (collected poems)
Why We Skeet (further collected poems)
…and listen to my music on Spotify.
Now, back to our daily articles about whatever I feel like…I watched the Bitcoin Documentary on HBO, so you get this article…
Bitcoin has hit $80,000— an all-time high. For those not familiar with the concept of a bitcoin maxi, it's an abbreviation for bitcoin maximalist. These are individuals who believe so strongly in this one cryptocurrency that are eclipses virtually every other belief that they could have. It is a religious level of fervor and can be obnoxious to be around. These individual's favorite things like an island for bitcoin enthusiast only. Visionary investors are investing in an island on a blockchain:
This is beautifully documented by the inimitable
on his Crypto Island limited series, which became Search Engine.But, with Bitcoin hitting new highs, I'm ready to write a little satire for my audience on this fine Sunday!I'm going to ask and imagine the Bitcoin maxi (BM), a series of questions that have nothing to do with Bitcoin, and see how that imagined conversation goes.
TFPs: What do you think is the most difficult problem facing psychedelic drug development in 2024?
BM: Bro, let's be real—psychedelic drug development in 2024 is hitting roadblocks because the traditional financial system is a total mess. Regulatory hurdles and funding issues are stifling innovation. If the industry embraced Bitcoin, we'd see a decentralized, transparent, and efficient funding model that could bypass these outdated systems. Bitcoin's blockchain could also ensure secure, immutable records for clinical trials, enhancing trust and accelerating approval processes. So, the biggest challenge? Not leveraging Bitcoin's revolutionary potential to transform the entire pharmaceutical landscape.
TFPs: When reviewing the FDA's regulatory guidance as it relates to the development of psychedelic compounds, particularly around the issue of function on blinding in clinical trials for psychedelic medicines, what do you see as the series of ways to meaningfully address the agency’s concerns in a post-Chevron era?